Refractoriness in Bipolar Disorder: Definitions and Evidence-Based Treatment

CNS Neuroscience and Therapeutics

Volumn 18, Issue 3, 2012, Pages 227-237

  Fountoulakis, Konstantinos N ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Aniconvulsants; Antidepressants; Antipsychotics; Bipolar disorder; Evidence based guidelines; Lithium; Mania; Mood stabilizers; Treatment

Indexed keywords

ALLOPURINOL; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; BENZODIAZEPINE; CARBAMAZEPINE; CLOZAPINE; DIPYRIDAMOLE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; FOLIC ACID; HALOPERIDOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PALIPERIDONE; PAROXETINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTRALINE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ADD ON THERAPY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CIRCADIAN RHYTHM; COGNITIVE THERAPY; COMPARATIVE EFFECTIVENESS; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HAMILTON SCALE; HUMAN; HYPOMANIA; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; MELANCHOLIA; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; SLEEP DEPRIVATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; YOUNG MANIA RATING SCALE;

ANTIMANIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; EVIDENCE-BASED MEDICINE; HUMANS; TREATMENT OUTCOME;

EID: 84858282619     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2011.00259.x     Document Type: Review

References (169)

1. Vieta E, Goikolea JM. Atypical antipsychotics: Newer options for mania and maintenance therapy. Bipolar Disord 2005;7(Suppl 4):21-33.
2. Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G. Treatment of bipolar depression: An update. J Affect Disord 2008;109:21-34.
3. Fountoulakis KN, Magiria S, Siamouli M, Panagiotidis P, Nimatoudis I, Iacovides A, Kaprinis GS. A seven-year follow-up of an extremely refractory bipolar I patient. CNS spectr 2007;12:733-734.
4. Fountoulakis KN, Vieta E, Sanchez-Moreno J, Kaprinis SG, Goikolea JM, Kaprinis GS. Treatment guidelines for bipolar disorder: A critical review. J Affect Disord 2005;86:1-10.
5. Fountoulakis KN, Vieta E, Siamouli M, et al. Treatment of bipolar disorder: A complex treatment for a multi-faceted disorder. Ann Gen Psychiatry 2007;6:27.
6. Manning JS. Burden of illness in bipolar depression. Prim Care Companion J Clin Psychiatry 2005;7:259-267.
7. Keller MB, Lavori PW, Kane JM, Gelenberg AJ, Rosenbaum JF, Walzer EA, Baker LA. Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium. Arch Gen Psychiatry 1992;49:371-376.
8. Tohen M, Waternaux CM, Tsuang MT. Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990;47:1106-1111.
9. Tohen M, Waternaux CM, Tsuang MT, Hunt AT. Four-year follow-up of twenty-four first-episode manic patients. J Affect Disord 1990;19:79-86.
10. Tohen M, Bowden CL, Calabrese JR, et al. Influence of sub-syndromal symptoms after remission from manic or mixed episodes. Br J Psychiatry 2006;189:515-519.
11. Schaff M, Fawcett J, Zajecka J. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry 1993;54:380-384.
12. Green A, Tohen M, Patel J. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry 2000;157:982-986.
13. Kramlinger K, Post R. Adding lithium carbonate to carbamazepine: Antimanic efficacy in treatment-resistant mania. Acta Psychiatr Scand 1989;79:378-385.
14. Altshuler L, Keck P, McElroy S. Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disord 1999;1:61-65.
15. McElroy S, Frye M, Denicoff K. Olanzapine in treatment-resistant bipolar disorder. J Affect Disord 1998;49:119-122.
16. Calabrese J, Bowden C, McElroy S. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999;156:1019-1023.
17. Kimmel S, Calabrese J, Woyshville M, Meltzer H. Clozapine in treatment-refractory mood disorders. J Clin Psychiatry 1994;55(Suppl B):91-93.
18. Calabrese J, Kimmel S, Woyshville M. Clozapine for treatment-refractory mania. Am J Psychiatry 1996;153:759-764.
19. Vieta E, Gasto C, Colom F, Martinez A, Otero A, Vallejo J. Treatment of refractory rapid cycling bipolar disorder with risperidone. J Clin Psychopharmacol 1998;18:172-174.
20. Sajatovic M, DiGiovanni S, Bastani B, Hattab H, Ramirez L. Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania. Psychopharmacol Bull 1996;32:55-61.
21. Ciapparelli A, Dell'Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: A 24-month naturalistic study. J Clin Psychiatry 2000;61:329-334.
22. Fountoulakis KN. An update of evidence-based treatment of bipolar depression: Where do we stand? Curr Opin Psychiatry 2010;23:19-24.
23. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: A systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008;11:999-1029.
24. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arc Gen psychiatry 1991;48:851-855.
25. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999;60(Suppl 22):7-11.
26. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998;59(Suppl 8):47-54.
27. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: A focus on treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):5-9.
28. Sheehan DV. Attaining remission in generalized anxiety disorder: Venlafaxine extended release comparative data. J Clin Psychiatry 2001;62(Suppl 19):26-31.
29. Kordy H, Kramer B, Palmer R, Papezova H, Pellet J, Richard M, Treasure J. Remission, recovery, relapse, and recurrence in eating disorders: Conceptualization and illustration of a validation strategy. J Clin Psychol 2002;58:833-846.
30. Möller H. Therapieresistenz auf Antidepressiva: Riskfaktoren und Behandlungsmoglichkeiten [Antidepressant resistance: Risk factors and treatment]. Nervenarzt 1991;62:658-669.
31. Inoue T, Nakagawa S, Kitaichi Y, et al. Long-term outcome of antidepressant-refractory depression: The relevance of unrecognized bipolarity. J Affect Disord 2006;95:61-67.
32. Pompili M, Serafini G, Del Casale A, et al. Improving adherence in mood disorders: The struggle against relapse, recurrence and suicide risk. Expert Rev Neurother 2009;9:985-1004.
33. Thase M, Rush A. Treatment-resistant depression. In: Bloom F, Kupfer D, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995; 1081-1097.
34. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: Recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 2009:7-14.
35. Doyle AC, Pollack MH. Establishment of remission criteria for anxiety disorders. J Clin Psychiatry 2003;64(Suppl 15):40-45.
36. Ninan PT. Dissolving the burden of generalized anxiety disorder. J Clin Psychiatry 2001;62(Suppl 19):5-10.
37. Leucht S, Beitinger R, Kissling W. On the concept of remission in schizophrenia. Psychopharmacology (Berl) 2007;194:453-461.
38. Thase ME. Redefining antidepressant efficacy toward long-term recovery. J Clin Psychiatry 1999;60(Suppl 6):15-19.
39. Ferrier IN. Characterizing the ideal antidepressant therapy to achieve remission. J Clin Psychiatry 2001;62(Suppl 26):10-15.
40. Cassidy CM, Norman R, Manchanda R, Schmitz N, Malla A. Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 Years. Schizophr Bull 2010;36:1001-1008.
41. Boden R, Sundstrom J, Lindstrom E, Lindstrom L. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr Res 2009;107:232-237.
42. Jager M, Messer T, Laux G, et al. Standardized remission criteria in schizophrenia: Descriptive validity and comparability with previously used outcome measures. Pharmacopsychiatry 2008;41:190-195.
43. Lasser RA, Nasrallah H, Helldin L, Peuskens J, Kane J, Docherty J, Tronco AT. Remission in schizophrenia: Applying recent consensus criteria to refine the concept. Schizophr Res 2007;96:223-231.
44. Wunderink L, Nienhuis F, Sytema, S. Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull 2007;33:792-796.
45. Harvey PD, Bellack AS. Toward a terminology for functional recovery in schizophrenia: Is functional remission a viable concept? Schizophr Bull 2009;35:300-306.
46. Faerden A, Nesvag R, Marder SR. Definitions of the term 'recovered' in schizophrenia and other disorders. Psychopathology 2008;41:271-278.
47. Buckley PF, Harvey PD, Bowie CR, Loebel A. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res 2007;94:99-106.
48. van Os J, Burns T, Cavallaro R, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006;113:91-95.
49. Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006;39:161-170.
50. Dunayevich E, Sethuraman G, Enerson M, Taylor CC, Lin D. Characteristics of two alternative schizophrenia remission definitions: Relationship to clinical and quality of life outcomes. Schizophr Res 2006;86:300-308.
51. Kopelowicz A, Liberman RP, Ventura J, Zarate R, Mintz J. Neurocognitive correlates of recovery from schizophrenia. Psychol Med 2005;35:1165-1173.
52. Andreasen NC, Carpenter WT, Jr., Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-449.
53. Peuskens J. The evolving definition of treatment resistance. J Clin Psychiatry 1999;60(Suppl 12):4-8.
54. Awad AG, Voruganti LN, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997;11:32-47.
55. Pi EH, Simpson GM. The treatment of refractory schizophrenia: Pharmacotherapy and clinical implications of blood level measurement of neuroleptics. Int Pharmacopsychiatry 1981;16:154-161.
56. Ghaemi SN, Pardo TB, Hsu DJ. Strategies for preventing the recurrence of bipolar disorder. J Clin Psychiatry 2004;65(Suppl 10):16-23.
57. Calabrese JR, Vieta E, El-Mallakh R, et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 2004;56:957-963.
58. Sachs G. Treatment-resistant bipolar depression. Psychiatr Clin North Am 1996;19:215-236.
59. Yatham LN, Calabrese JR, Kusumakar V. Bipolar depression: Criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord 2003;5:85-97.
60. Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010;71:150-162.
61. Zornberg GL, Pope HG, Jr. Treatment of depression in bipolar disorder: New directions for research. J Clin Psychopharmacol 1993;13:397-408.
62. Menza M, Easton J, Flaum M, Frank D, Goldberg I, Michell M. Approaches to the treatment of lithium-resistant mania. Psychiatr Med 1988;6:73-87.
63. Goldberg J, Garno J, Leon A, Koosis J, Portera L. Rapid titration of mood stabilizers predicts remission from mixed or pure mania in bipolar patients. J Clin Psychiatry 1998;59:151-158.
64. Keck PE, Jr., Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: A three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003;160:741-748.
65. Potkin SG, Keck PE, Jr., Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: A 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005;25:301-310.
66. Keck PE, Jr., Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-1658.
67. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: A 3-week placebo-controlled study. J Psychopharmacol 2006;20:536-546.
68. Keck P, sanchez R, Torbeyns A, Marcus R, McQuade R, Forbes A. Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized placebo- and lithium-controlled study (Study CN138-135). American Psychiatric Association 160th Annual Meeting. San Diego CA, USA, 2007.
69. Keck PE, Jr., McElroy SL. Definition, evaluation, and management of treatment refractory mania. Psychopharmacol Bull 2001;35:130-148.
70. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: Results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28:13-20.
71. Tohen M, Frank E, Bowden CL, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009;11:453-473.
72. Furukawa TA, Konno W, Morinobu S, Harai H, Kitamura T, Takahashi K. Course and outcome of depressive episodes: Comparison between bipolar, unipolar and subthreshold depression. Psychiatry Res 2000;96:211-220.
73. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th Edition, Text Revision, DSM-IV-TR. Washington, DC: American Psychiatric Publishing, 2000.
74. Calabrese JR, Goldberg JF, Ketter TA, et al. Recurrence in bipolar I disorder: A post hoc analysis excluding relapses in two double-blind maintenance studies. Biol Psychiatry 2006;59:1061-1064.
75. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994;271:918-924.
76. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66:111-121.
77. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: Results of four double-blind placebo-controlled trials. Bipolar Disord 2006;8:15-27.
78. Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry 2009;194:40-48.
79. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005;15:573-585.
80. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999;156:702-709.
81. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000;57:841-849.
82. Chengappa KN, Baker RW, Shao L, et al. Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disord 2003;5:1-5.
83. Gopal S, Steffens DC, Kramer ML, Olsen MK. Symptomatic remission in patients with bipolar mania: Results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry 2005;66:1016-1020.
84. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011-1017.
85. Akiskal H. Mood disorders. In: Sadock B, Sadock V, editors. Comprehensive Textbook of Psychiatry. Philadelphia: Lippincott Williams & Wilkins, 2000;1338-1377.
86. Young AH, McElroy H, Chang W, Olausson B, Paulsson B, Brecher M. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN i). 3rd Biennial Conference of the International Society for Bipolar Disorders. Delhi, India, 2008.
87. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-1088.
88. Calabrese JR, Keck PE, Jr., Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-1360.
89. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26:600-609.
90. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999;60:79-88.
91. Nassir Ghaemi S. Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. Bipolar Disord 2008;10:957-968.
92. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-1722.
93. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-912.
94. McElroy S, Young A, Carlsson A, et al. Double-blind, randomized, placebo-controlled study of quetiapine and paroxetine in adults with bipolar depression (EMBOLDEN II). Conference of the International Society for Bipolar Disorders; Delhi and Agra, India, 2008.
95. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163:247-256.
96. Amsterdam JD, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: A double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol 2005;20:257-264.
97. Ball JR, Mitchell PB, Corry JC, Skillecorn A, Smith M, Malhi GS. A randomized controlled trial of cognitive therapy for bipolar disorder: Focus on long-term change. J Clin Psychiatry 2006;67:277-286.
98. Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: A 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 2007;64:419-426.
99. Colom F, Vieta E, Sanchez-Moreno J, et al. Stabilizing the stabilizer: Group psychoeducation enhances the stability of serum lithium levels. Bipolar Disord 2005;7(Suppl 5):32-36.
100. Reinares M, Vieta E, Colom F, et al. Impact of a psychoeducational family intervention on caregivers of stabilized bipolar patients. Psychother Psychosom 2004;73:312-319.
101. Colom F, Vieta E, Sanchez-Moreno J, et al. Psychoeducation in bipolar patients with comorbid personality disorders. Bipolar Disord 2004;6:294-298.
102. Colom F, Vieta E, Reinares M, et al. Psychoeducation efficacy in bipolar disorders: Beyond compliance enhancement. J Clin Psychiatry 2003;64:1101-1105.
103. Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003;60:402-407.
104. Scott J, Colom F, Vieta E. A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders. Int J Neuropsychopharmacol 2007;10:123-129.
105. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-1226.
106. Zarate CA, Jr., Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004;161:169-171.
107. Post RM, Altshuler LL, Frye MA, et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord 2001;3:259-265.
108. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: Comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006;189:124-131.
109. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006;163:232-239.
110. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression-lack of manic induction. J Affect Disord 2005;87:121-130.
111. Keck PE, Jr., Corya SA, Altshuler LL, et al. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J Clin Psychiatry 2005;66:611-616.
112. Bottlender R, Rudolf D, Strauss A, Moller HJ. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord 2001;63:79-83.
113. Angst J. Switch from depression to mania-a record study over decades between 1920 and 1982. Psychopathology 1985;18:140-154.
114. Perlis RH, Ostacher MJ, Goldberg JF, et al. Transition to mania during treatment of bipolar depression. Neuropsychopharmacology 2010;35:2545-2552.
115. Garfinkel PE, Stancer HC, Persad E. A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania. J Affect Disord 1980;2:279-288.
116. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: A double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002;159:1146-1154.
117. Chou JC, Czobor P, Charles O, et al. Acute mania: Haloperidol dose and augmentation with lithium or lorazepam. J Clin Psychopharmacol 1999;19:500-505.
118. Lenox RH, Newhouse PA, Creelman WL, Whitaker TM. Adjunctive treatment of manic agitation with lorazepam versus haloperidol: A double-blind study. J Clin Psychiatry 1992;53:47-52.
119. Small JG, Klapper MH, Marhenke JD, Milstein V, Woodham GC, Kellams JJ. Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychopharmacol Bull 1995;31:265-272.
120. Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. Arch Gen Psychiatry 1984;41:165-170.
121. Tohen M, Bowden CL, Smulevich AB, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008;192:135-143.
122. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003;182:141-147.
123. Juruena MF, Ottoni GL, Machado-Vieira R, et al. Bipolar I and II disorder residual symptoms: Oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:94-99.
124. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002;59:62-69.
125. Houston JP, Ahl J, Meyers AL, Kaiser CJ, Tohen M, Baldessarini RJ. Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. J Clin Psychiatry 2006;67:1246-1252.
126. Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA, Sweitzer DE. Quetiapine with lithium or divalproex for the treatment of bipolar mania: A randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6:213-223.
127. Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004;24:599-606.
128. Yatham LN, Vieta E, Young AH, Moller HJ, Paulsson B, Vagero M. A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. Int Clin Psychopharmacol 2007;22:212-220.
129. Vieta E, T'Joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: A placebo-controlled study. Am J Psychiatry 2008;165:1316-1325.
130. Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: A prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol 2000;20:195-203.
131. Weisler R, Dunn J, English P. Adjunctive Ziprasidone for acute bipolar mania: Randomized, placebo-controlled trial. 4th International Forum on Mood and Anxiety Disorders. Monte Carlo, Monaco, 2003.
132. Roy Chengappa KN, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: A randomized, placebo-controlled trial. J Clin Psychiatry 2006;67:1698-1706.
133. Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss CB, Johnson WE. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984;41:1096-1104.
134. Prien RF, Klett CJ, Caffey EM, Jr. Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness. Arch Gen Psychiatry 1973;29:420-425.
135. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Nayak DD, Howard A. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: A prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982;39:1065-1069.
136. Altshuler LL, Post RM, Hellemann G, et al. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: A blinded, randomized study. J Clin Psychiatry 2009;70:450-457.
137. Schaffer A, Zuker P, Levitt A. Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. J Affect Disord 2006;96:95-99.
138. Pilhatsch M, Wolf R, Winter C, Lewitzka U, Bauer M. Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: A reanalysis of a randomized, double-blind study. J Affect Disord 2010;126:453-457.
139. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000;157:124-126.
140. Van Der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: A multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:223-231.
141. Brown E, Dunner DL, McElroy SL, Keck PE, Adams DH, Degenhardt E, et al. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2009;12:773-782.
142. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008;109:251-263.
143. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment for patients with bipolar I disorder: Results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009;166:476-488.
144. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-345.
145. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar i disorder: A 6-Month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010;71:130-137.
146. Gyulai L, Bowden CL, McElroy SL, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003;28:1374-1382.
147. Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009;11:827-839.
148. Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): A randomised open-label trial. Lancet 2010;375:385-395.
149. Fountoulakis KN. The BALANCE trial. Lancet 2010;375:1343-1344; author reply 4.
150. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997;58:470-478.
151. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999;156:1164-1169.
152. Machado-Vieira R, Soares JC, Lara DR, et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry 2008;69:1237-1245.
153. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008;23:87-94.
154. Behzadi AH, Omrani Z, Chalian M, Asadi S, Ghadiri M. Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: A double-blind randomized controlled trial. Acta psychiatrica Scandinavica 2009;120:441-445.
155. Zarate CA, Jr., Payne JL, Singh J, et al. Pramipexole for bipolar II depression: A placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60.
156. Eden Evins A, Demopulos C, Yovel I, et al. Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord 2006;8:168-174.
157. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64:468-475.
158. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007;164:1242-1249.
159. Fountoulakis KN, Siamouli M, Panagiotidis P, Magiria S, Kantartzis S, Iacovides A, Kaprinis GS. Ultra short manic-like episodes after antidepressant augmentation with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:891-892.
160. Hiremani RM, Thirthalli J, Tharayil BS, Gangadhar BN. Double-blind randomized controlled study comparing short-term efficacy of bifrontal and bitemporal electroconvulsive therapy in acute mania. Bipolar Disord 2008;10:701-707.
161. Kessler U, Vaaler AE, Schoyen H, et al. The study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder. BMC Psychiatry 2010;10:16.
162. Daly JJ, Prudic J, Devanand DP, et al. ECT in bipolar and unipolar depression: Differences in speed of response. Bipolar Disord 2001;3:95-104.
163. Small JG, Klapper MH, Kellams JJ, Miller MJ, Milstein V, Sharpley PH, Small IF. Electroconvulsive treatment compared with lithium in the management of manic states. Arch Gen Psychiatry 1988;45:727-732.
164. Sikdar S, Kulhara P, Avasthi A, Singh H. Combined chlorpromazine and electroconvulsive therapy in mania. Br J Psychiatry 1994;164:806-810.
165. Dell'Osso B, Mundo E, D'Urso N, et al. Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drug-resistant bipolar depression. Bipolar Disord 2009;11:76-81.
166. Dolberg OT, Dannon PN, Schreiber S, Grunhaus L. Transcranial magnetic stimulation in patients with bipolar depression: A double blind, controlled study. Bipolar Disord 2002;4(Suppl 1):94-95.
167. Nahas Z, Kozel FA, Li X, Andserson B, George MS. Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: A pilot study of acute safety and efficacy. Bipolar Disord 2003;5:40-47.
168. Saba G, Rocamora JF, Kalalou K, Benadhira R, Plaze M, Lipski H, Januel D. Repetitive transcranial magnetic stimulation as an add-on therapy in the treatment of mania: A case series of eight patients. Psychiatry Res 2004;128:199-202.
169. Wu JC, Kelsoe JR, Schachat C, et al. Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder. Biol Psychiatry 2009;66:298-301.